[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 25 of about 25
1. Nitta M, Hoshi A, Shinozaki T, Soeda S, Kawakami M, Kin H, Nakajima N, Hanai K, Kato S, Nomoto T, Usui Y, Terachi T: [Granulocytic sarcoma of the prostate]. Hinyokika Kiyo; 2010 Sep;56(9):521-5
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Granulocytic sarcoma of the prostate].
  • The level of serum prostate specific antigen was slightly elevated (4.66 ng/ml), and digital rectal examination revealed a stony hard prostate mass.
  • Clinical imaging confirmed the absence of any other lesions, and granulocytic sarcoma of the prostate was subsequently diagnosed.
  • We treated the cancer with radiotherapy at a dose of 40 Gy and dysuria improved.
  • Four months after initial presentation, the patient developed acute myeloid leukemia [M2 by French-American-British classification].
  • Induction chemotherapy was initiated, and the patient was successfully induced to complete remission.
  • Despite salvage chemotherapy, he died of brain hemorrhage twenty-four months after complete remission.
  • [MeSH-major] Prostatic Neoplasms / pathology. Sarcoma, Myeloid / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20940529.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


2. Cho SI, Park YH, Cho JH, Ryoo BY, Yang SH, Youn SM, Ko JS: Extraskeletal Ewing's sarcoma of the head and neck presenting as blindness. Korean J Intern Med; 2007 Jun;22(2):133-7
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extraskeletal Ewing's sarcoma of the head and neck presenting as blindness.
  • Extraskeletal Ewing's sarcoma is rarely found in the head and neck regions.
  • We report an unusual case of extraskeletal Ewing's Sarcoma of the parapharynx region in a 49-year-old man who presented with blindness.
  • The final diagnosis was extraskeletal Ewing's sarcoma after biopsy of the internal jugular vein thrombosis by histopathological evaluation and immunohistochemical assay.
  • In addition, the patient was diagnosed as having adenocarcinoma of the rectum by biopsy of the rectal mass.
  • The patient was treated with systemic chemotherapy and showed improved response with durable remission.
  • [MeSH-major] Blindness. Head and Neck Neoplasms / pathology. Sarcoma, Ewing / pathology
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Humans. Male. Middle Aged. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • Genetic Alliance. consumer health - Blindness.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Laryngol Otol. 2000 Jan;114(1):73-5 [10789420.001]
  • [Cites] Spine (Phila Pa 1976). 2000 Aug 1;25(15):1996-9 [10908947.001]
  • [Cites] Eur Urol. 2001 May;39(5):613-7 [11464048.001]
  • [Cites] Stroke. 1996 Feb;27(2):243-6 [8571417.001]
  • [Cites] Cancer. 1975 Jul;36(1):240-51 [1203852.001]
  • [Cites] Am J Surg Pathol. 1994 May;18(5):486-94 [7513503.001]
  • [Cites] Am J Pathol. 1995 Dec;147(6):1799-810 [7495304.001]
  • [Cites] Radiology. 1969 Jun;92(7):1501-9 [5799839.001]
  • (PMID = 17616033.001).
  • [ISSN] 1226-3303
  • [Journal-full-title] The Korean journal of internal medicine
  • [ISO-abbreviation] Korean J. Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide
  • [Other-IDs] NLM/ PMC2687615
  •  go-up   go-down


3. Ferenschild FT, Vermaas M, Verhoef C, Ansink AC, Kirkels WJ, Eggermont AM, de Wilt JH: Total pelvic exenteration for primary and recurrent malignancies. World J Surg; 2009 Jul;33(7):1502-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Total pelvic exenteration (TPE) is an exenterative operation for these advanced tumors and involves en bloc resection of the rectum, bladder, and internal genital organs (prostate/seminal vesicles or uterus, ovaries and/or vagina).
  • METHODS: Between 1994 and 2008, a TPE was performed in 69 patients with pelvic cancer; 48 with rectal cancer (32 primary and 16 recurrent), 14 with cervical cancer (1 primary and 13 recurrent), 5 with sarcoma (3 primary and 2 recurrent), 1 with primary vaginal, and 1 with recurrent endometrial carcinoma.
  • Ten patients were treated with neoadjuvant chemotherapy and 66 patients with preoperative radiotherapy to induce down-staging.
  • Five-year local control for primary locally advanced rectal cancer, recurrent rectal cancer, and cervical cancer was 89%, 38%, and 64%, respectively.
  • Overall survival after 5 years for primary locally advanced rectal cancer, recurrent rectal cancer, and cervical cancer was 66%, 8%, and 45%.
  • CONCLUSIONS: Total pelvic exenteration is accompanied with considerable morbidity, but good local control and acceptable overall survival justifies the use of this extensive surgical technique in most patients, especially patients with primary locally advanced rectal cancer and recurrent cervical cancer.
  • [MeSH-minor] Adult. Aged. Brachytherapy / methods. Cohort Studies. Disease-Free Survival. Endometrial Neoplasms / mortality. Endometrial Neoplasms / pathology. Endometrial Neoplasms / radiotherapy. Endometrial Neoplasms / surgery. Female. Hospital Mortality / trends. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Postoperative Complications / mortality. Probability. Prognosis. Proportional Hazards Models. Quality of Life. Radiotherapy, Adjuvant. Rectal Neoplasms / mortality. Rectal Neoplasms / pathology. Rectal Neoplasms / radiotherapy. Rectal Neoplasms / surgery. Retrospective Studies. Risk Assessment. Survival Analysis. Uterine Cervical Neoplasms / mortality. Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / radiotherapy. Uterine Cervical Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Surg Oncol. 2003 Nov;29(9):743-6 [14602493.001]
  • [Cites] Dig Surg. 2003;20(3):192-9; discussion 200 [12759498.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Jan 1;58(1):106-12 [14697427.001]
  • [Cites] Gynecol Oncol. 2004 Feb;92(2):680-3 [14766266.001]
  • [Cites] Eur J Surg Oncol. 2004 Nov;30(9):972-5 [15498643.001]
  • [Cites] Lancet. 1986 Nov 1;2(8514):996-9 [2430152.001]
  • [Cites] Arch Surg. 1994 Apr;129(4):390-5; discussion 395-6 [8154965.001]
  • [Cites] Ann Surg Oncol. 1998 Jul-Aug;5(5):399-406 [9718168.001]
  • [Cites] Ann Surg. 1998 Sep;228(3):355-65 [9742918.001]
  • [Cites] J Urol. 1999 Apr;161(4):1057-66 [10081838.001]
  • [Cites] CA Cancer J Clin. 1999 Jan-Feb;49(1):33-64, 1 [10200776.001]
  • [Cites] Gynecol Oncol. 1999 Oct;75(1):99-102 [10502433.001]
  • [Cites] Surg Clin North Am. 1950 Oct;30(5):1511-21 [14782163.001]
  • [Cites] Dis Colon Rectum. 2004 Dec;47(12):2047-53; discussion 2053-4 [15657653.001]
  • [Cites] Gynecol Oncol. 2005 May;97(2):524-8 [15863155.001]
  • [Cites] Int J Gynecol Cancer. 2005 May-Jun;15(3):475-82 [15882172.001]
  • [Cites] Dis Colon Rectum. 2005 May;48(5):918-28 [15785886.001]
  • [Cites] Int J Gynecol Cancer. 2005 Jul-Aug;15(4):624-9 [16014116.001]
  • [Cites] Gynecol Oncol. 2005 Oct;99(1):153-9 [16054678.001]
  • [Cites] Dis Colon Rectum. 2006 Sep;49(9):1257-65 [16912909.001]
  • [Cites] Eur J Surg Oncol. 2007 May;33(4):452-8 [17071043.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2007 Oct;134(2):243-8 [16950559.001]
  • [Cites] Cancer. 1948 Jul;1(2):177-83 [18875031.001]
  • [Cites] Dis Colon Rectum. 1999 Nov;42(11):1438-48 [10566532.001]
  • [Cites] J Am Coll Surg. 2000 Jan;190(1):78-83 [10625236.001]
  • [Cites] World J Surg. 2001 Dec;25(12):1546-9 [11775189.001]
  • [Cites] Dis Colon Rectum. 2002 Aug;45(8):1078-84 [12195193.001]
  • [Cites] Dis Colon Rectum. 2003 Dec;46(12):1619-25 [14668586.001]
  • (PMID = 19421811.001).
  • [ISSN] 1432-2323
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2691931
  •  go-up   go-down


Advertisement
4. Carron M, Innocente F, Veronese S, Miotto D, Pilati P, Rossi CR, Ori C: Subarachnoid anesthesia for loco-regional antiblastic perfusion with circulatory block (stop-flow perfusion). Minerva Anestesiol; 2006 Jan-Feb;72(1-2):37-45

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: Loco-regional antiblastic perfusion with circulatory block (stop-flow perfusion, SFP) is a procedure designed to treat solid tumors of the limb and pelvis in an advanced stage, like melanoma, sarcoma of the soft tissues and colon-rectal cancer.
  • The aim of this study was to evaluate if subarachnoid anesthesia could represent a safe and suitable anesthetic technique for this procedure.
  • METHODS: Thirty SFP procedures were performed in the angiographic room, 15 for the treatment of lower-limb neoplasias and 15 for pelvic neoplasias.
  • The use of any anesthetic and analgesic drug, eventually used in the intra- or postoperative period, was recorded.
  • Intraoperative pain control was almost complete with one exception, when the procedure lasted unusually long.
  • Pain control was satisfying immediately after the procedure as well: only in 3 cases were non-opiod analgesics administered within the first 6 h.
  • CONCLUSIONS: Spinal subarachnoid anesthesia has proven to be an effective, safe, and easy-to-manage technique for carrying out SFP procedure in a non-conventional environment such as an angiographic room.
  • [MeSH-major] Anesthesia, Spinal. Heart Arrest, Induced. Neoplasms / therapy. Perfusion. Subarachnoid Space

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16407805.001).
  • [ISSN] 0375-9393
  • [Journal-full-title] Minerva anestesiologica
  • [ISO-abbreviation] Minerva Anestesiol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Anesthetics, Local; Y8335394RO / Bupivacaine
  •  go-up   go-down


5. Rivero Fernández M, García Martos M, Sanz Moya P, Vázquez Romero M, Fernández Amago MT, García Benayas MT, Sánchez-Pobre Bejarano P: [Kaposi's sarcoma with colorectal and anal canal involvement]. Gastroenterol Hepatol; 2010 Aug-Sep;33(7):508-11
MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Kaposi's sarcoma with colorectal and anal canal involvement].
  • [Transliterated title] Sarcoma de Kaposi con afectación colorrectal y del canal anal.
  • Kaposi's sarcoma (KS) is a low-grade vascular tumor, with four main variants, one of which is fairly prevalent in HIV-infected patients.
  • The gastrointestinal tract is involved in 40% of patients, but rectal and anal canal involvement is exceptional.
  • The patient was treated with highly active antiretroviral therapy and systemic chemotherapy, with partial response.
  • Local radiation therapy of the rectum produced local remission.
  • [MeSH-major] Anus Neoplasms. Colorectal Neoplasms. Neoplasms, Multiple Primary. Sarcoma, Kaposi

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] .
  • (PMID = 20630624.001).
  • [ISSN] 0210-5705
  • [Journal-full-title] Gastroenterología y hepatología
  • [ISO-abbreviation] Gastroenterol Hepatol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


6. Bosincu L, Massarelli G, Cossu Rocca P, Isaac MA, Nogales FF: Rectal endometrial stromal sarcoma arising in endometriosis: report of a case. Dis Colon Rectum; 2001 Jun;44(6):890-2
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rectal endometrial stromal sarcoma arising in endometriosis: report of a case.
  • PURPOSE: Endometriosis of the rectovaginal septum can harbor different types of secondary tumors that may involve the rectal wall and protrude into its lumen, thus making diagnosis difficult.
  • Extrauterine low-grade endometrial stromal sarcoma may rarely arise in endometriosis.
  • Histopathologically, primary endometriotic foci were found in close relationship with an endometrial stromal sarcoma which invaded the rectal wall.
  • The patient was treated by surgery and subsequent chemotherapy and was alive and well 20 months later.
  • CONCLUSIONS: Endometriosis and its possible malignant changes should be taken into account in the differential endoscopic diagnosis of rectal masses in females.
  • [MeSH-major] Endometrial Neoplasms / etiology. Endometriosis / complications. Sarcoma / etiology

  • Genetic Alliance. consumer health - Endometrial Stromal Sarcoma.
  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11391154.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


7. Melichar B, Voboril Z, Nozicka J, Cerman J Jr, Melicharová K, Mergancová J, Filip S, Krajina A, Voboril R, Jandík P: Hepatic arterial infusion chemotherapy in sarcoma liver metastases: a report of 6 cases. Tumori; 2005 Jan-Feb;91(1):19-23
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic arterial infusion chemotherapy in sarcoma liver metastases: a report of 6 cases.
  • AIMS AND BACKGROUND: Liver metastases in patients with sarcoma are rare and associated with a poor prognosis.
  • The experience with liver-directed therapies, eg hepatic arterial infusion, in these patients is limited.
  • METHODS: Six patients with sarcoma metastatic to the liver (4 patients with gastrointestinal stromal tumors and 2 patients with leiomyosarcoma) were treated by hepatic arterial infusion in our center over a 12-year period.
  • RESULTS: None of the 5 assessable patients responded to the therapy, and liver metastases progressed in all patients.
  • CONCLUSIONS: Hepatic arterial infusion has little efficacy in the treatment of sarcoma metastatic to the liver.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Hepatic Artery. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Sarcoma / drug therapy. Sarcoma / secondary
  • [MeSH-minor] Adult. Aged. Female. Humans. Infusions, Intra-Arterial. Jejunal Neoplasms / pathology. Male. Middle Aged. Rectal Neoplasms / pathology. Retroperitoneal Neoplasms / pathology. Retrospective Studies. Stomach Neoplasms / pathology. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15850000.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Petković M, Zamolo G, Muhvić D, Coklo M, Stifter S, Antulov R: The first report of extraosseous Ewing's sarcoma in the rectovaginal septum. Tumori; 2002 Jul-Aug;88(4):345-6
MedlinePlus Health Information. consumer health - Vaginal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The first report of extraosseous Ewing's sarcoma in the rectovaginal septum.
  • AIMS AND BACKGROUND: To report an extremely rare case of Ewing's sarcoma located in the rectovaginal septum.
  • Ewing's sarcoma is a highly malignant neoplasm of bone, which usually occurs during childhood.
  • Common extraosseous localizations of Ewing's sarcoma include the trunk, extremities, uterus, cervix and vagina.
  • The mass had a size of 9 x 6 cm, a soft tissue consistency, was partially movable and the patient felt the pain during palpation.
  • Computed tomography (CT) showed an inhomogeneous expansive mass in the rectovaginal septum measuring 8.7 x 6.1 cm, without any signs of rectum or bladder invasion.
  • Immunohistology with the monoclonal antibody CD99 (MIC-2 gene product, Ewing's sarcoma marker, clone 12E7, DAKO A/S, Glostrup, Denmark) revealed an extraosseous Ewing's sarcoma.
  • The patient was treated with chemotherapy followed by whole-pelvis external beam radiation and intracavitary brachytherapy.
  • RESULTS: A residual mass measuring 3.5 x 2.5 cm was visible on a control CT scan 18 months after treatment; however, the patient was feeling well and refused surgery to remove the residual mass.
  • CONCLUSIONS: To our knowledge this is the first reported case of extraosseous Ewing's sarcoma in the rectovaginal septum.
  • [MeSH-major] Rectal Neoplasms / therapy. Sarcoma, Ewing / therapy. Vaginal Neoplasms / therapy

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12400989.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Castle JT, Thompson LD: Kaposi sarcoma of major salivary gland origin: A clinicopathologic series of six cases. Cancer; 2000 Jan 1;88(1):15-23
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Kaposi sarcoma of major salivary gland origin: A clinicopathologic series of six cases.
  • BACKGROUND: Kaposi sarcoma (KS), one of the defining tumors of acquired immune deficiency syndrome (AIDS), is rarely identified in the major salivary glands.
  • Patients were treated with surgical excision (n = 6), followed by chemotherapy (n = 1) for the single patient with other foci of KS (rectal).
  • Although rare, it is important to consider KS in the differential diagnosis of other AIDS-related salivary gland manifestations (infections and tumors).
  • [MeSH-major] AIDS-Related Opportunistic Infections / diagnosis. Herpesvirus 8, Human. Salivary Gland Neoplasms / diagnosis. Sarcoma, Kaposi / diagnosis
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Humans. Immunohistochemistry. In Situ Hybridization. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - HIV/AIDS and Infections.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 American Cancer Society.
  • (PMID = 10618601.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


10. Willett CG: Intraoperative radiation therapy. Int J Clin Oncol; 2001 Oct;6(5):209-14
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraoperative radiation therapy.
  • The modern use of intraoperative radiation therapy (IORT) was initiated by the studies of Abe and colleagues at the University of Kyoto.
  • Most importantly, this high dose of additional radiation treatment yields improved local control of selected tumors.
  • Treatment programs of external beam radiation therapy, surgical resection, and IORT for patients with locally advanced primary and recurrent rectal carcinoma and retroperitoneal sarcoma have yielded excellent local control and higher survival rates.
  • The future of IORT will be in the successful integration of this therapy into multimodality treatment programs of chemotherapy, external beam irradiation, and surgery for locally advanced malignancies.
  • [MeSH-major] Carcinoma / radiotherapy. Rectal Neoplasms / radiotherapy. Retroperitoneal Neoplasms / radiotherapy. Sarcoma / radiotherapy
  • [MeSH-minor] Animals. Combined Modality Therapy. Dogs. Humans. Intraoperative Period. Male. Radiation Tolerance. Radiotherapy, High-Energy. Survival Rate

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11723741.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 20
  •  go-up   go-down


11. Raffaelli R, Piazzola E, Zanconato G, Fedele L: A rare case of extrauterine adenosarcoma arising in endometriosis of the rectovaginal septum. Fertil Steril; 2004 Apr;81(4):1142-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To present a rare case of endometrial stromal sarcoma arising in endometriosis of the rectovaginal septum.
  • SETTING: Academic tertiary referral center for endometriosis treatment.
  • PATIENT(S): A 50-year-old woman with a history of endometriosis presented with catamenial rectal pain and deep dyspareunia.
  • Although extemporary pathology confirmed endometriosis, the final histologic diagnosis was extrauterine adenosarcoma in the rectovaginal septum.
  • Subsequent radiotherapy and chemotherapy were administered.
  • RESULT(S): The patient was in good health for 2 years after the initial surgery, when she developed a new lesion at the site of the previous resection.
  • After postoperative therapy, the patient is now without evidence of disease.
  • CONCLUSION(S): Malignant transformation of endometriosis should be considered in the differential diagnosis of a new pelvic lesion in a patient with a history of endometriosis.
  • [MeSH-major] Adenosarcoma / etiology. Endometriosis / complications. Rectal Diseases / complications. Rectal Neoplasms / etiology. Vaginal Diseases / complications. Vaginal Neoplasms / etiology


12. Deutsch M, Wollman MR: Radiotherapy for metastases to the mandible in children. J Oral Maxillofac Surg; 2002 Mar;60(3):269-71
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Six children had a neuroblastoma, 1 had angiosarcoma of the liver, 1 had adenocarcinoma of the rectum, and 1 had peripheral primitive neuroectodermal tumor (Ewing's sarcoma) of the spine.
  • All children had received chemotherapy.
  • RESULTS: All children died of disseminated disease at 5 to 59 months from their initial diagnosis, 5 to 29 months from the detection of metastases to bone, and only 6 days to 17 months (median, 2 months) from the first treatment of metastases to the mandible.
  • CONCLUSIONS: The outlook for children with metastases that involve the mandible is very poor, and we recommend short intensive courses of radiotherapy consisting of 1 to 3 treatments to total doses of 400 to 1,200 cGy for palliation of pain.
  • [MeSH-minor] Adenocarcinoma / radiotherapy. Adenocarcinoma / secondary. Adolescent. Child. Child, Preschool. Female. Hemangiosarcoma / radiotherapy. Hemangiosarcoma / secondary. Humans. Infant. Liver Neoplasms / pathology. Male. Neuroblastoma / radiotherapy. Neuroblastoma / secondary. Pain, Intractable / radiotherapy. Radiotherapy Dosage. Rectal Neoplasms / pathology. Retrospective Studies. Sarcoma, Ewing / radiotherapy. Sarcoma, Ewing / secondary. Spinal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 American Association of Oral and Maxillofacial Surgeons
  • (PMID = 11887137.001).
  • [ISSN] 0278-2391
  • [Journal-full-title] Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons
  • [ISO-abbreviation] J. Oral Maxillofac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Wanebo HJ, Begossi G, Belliveau J, Gustafson E: Isolated chemotherapeutic perfusion as neoadjuvant therapy for advanced/unresectable pelvic malignancy. J Clin Oncol; 2009 May 20;27(15_suppl):2555

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated chemotherapeutic perfusion as neoadjuvant therapy for advanced/unresectable pelvic malignancy.
  • : 2555 Background: Isolated pelvic perfusion (IPP) provides higher tissue drug levels than high-dose systemic therapy and may enhance resectability and survival in patients failing chemo radiation ± surgery.
  • METHODS: 42 patients had advanced (irradiated) rectal cancer, 8 pts had advanced anorectal cancer, 5 patients had sarcoma.
  • Chemotherapy agents included 5FU, (1,500-2,000mg/M<sup>2</sup>), cisplatinum (100mg/M<sup>2</sup>), Oxaliplatin and mitomycin (10-20mg/M<sup>2</sup>) for epithelial cancer and selected agents (Adriamycin, Ifosamide, DTIC, Phenyl Alanine Mustard (PAM) for the remaining tumors: 6 pts received high dose PAM (110/M<sup>2</sup>), Paclitaxel 60mg/m<sup>2</sup> and Cisplatin 150mg/m<sup>2</sup>, 3 required stem cell support (advanced M (1 pt), SCC (1 pt), Endometrial ca (1pt).
  • RESULTS: Palliative IPP for advanced rectal cancer pts provided significant pain control (1-4 months) in 11 of 14 pts with narcotic resistant pain and induced tumor regression in 6 pts.
  • Preoperative perfusion in 26 advanced rectal cancer pts induced a complete path response (in pelvis) in 2 pts and significant regression in 11 pts rendering them resectable.
  • It was 30 months in 8 pts with advanced anorectal squamous cancer (1pt survived >90 mos), 20 months in 4 patients with endometrial/ovarian recurrence, (1 died NED >48 mos), 13 mos in 4 melanoma pts and only 5 months in 5 pts pelvic sarcoma (4-34 mos-NED).
  • CONCLUSIONS: IPP with high dose chemo therapy has promise in palliating or augmenting resectability of advanced pelvic malignancy persisting after conventional surgical and chemoradiation therapy.
  • Stem cell support and biologic therapy merit further exploration.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961873.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Merimsky O, Soyfer V, Corn B: Hypofractionated radiation therapy for palliation of sarcoma metastases. J Clin Oncol; 2009 May 20;27(15_suppl):e21517

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypofractionated radiation therapy for palliation of sarcoma metastases.
  • : e21517 Background: RT is our preferred modality for local palliation of metastatic STS, regardless of systemic chemotherapy.
  • While a protracted course of RT may be given as postoperative adjuvant treatment, a short and intense course of RT is usually needed for rapid palliation and local control of metastatic disease.
  • RT doses within the range of 60 - 70 Gy are usually needed to be delivered in order to eradicate microscopic disease, while 50 Gy doses are needed for other malignancies such as breast or rectal cancer.
  • METHODS: Seventeen patients, 8 women and 9 men, at a median age of 61 years (range 53-95 years) had symptomatic metastatic sarcoma, and required rapid palliation.
  • All the patients were treated by a short and intensive course of administration: 39 Gy were given in 13 fractions of 3 Gy/day, 5 times a week.
  • The treatment was well tolerated.
  • Late side effects included skin pigmentation and induration of irradiated soft tissues.
  • Among 5 lesions which were irradiated as an adjunctive treatment following resection, no local recurrence was observed.
  • CONCLUSIONS: The results of this series, although limited in size, point to the safety and feasibility of hypofractionated RT for palliation of musculoskeletal metastases from sarcoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963448.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Gore L, Holden SN, Basche M, Raj SK, Arnold I, O'Bryant C, Witta S, Rohde B, McCoy C, Eckhardt SG: Updated results from a phase I trial of the histone deacetylase (HDAC) inhibitor MS-275 in patients with refractory solid tumors. J Clin Oncol; 2004 Jul 15;22(14_suppl):3026

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histone H3 and H4 acetylation was analyzed in peripheral blood mononuclear cells (PBMCs) by immunohistochemical detection.
  • No drug related grade (gr) 4 adverse events (AEs) have been reported.
  • The most common drug related AEs were gr 1-3 hypophosphatemia, asthenia, nausea and anorexia.
  • One pt with melanoma continued to exhibit a partial response (Sch A), and 1 pt each with Ewing's sarcoma (Sch A), rectal carcinoma (Sch A) and melanoma (Sch B) had stable disease after 60+, 38+ and 20+ weeks of therapy, respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28015195.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Willett CG, Czito BG, Tyler DS: Intraoperative radiation therapy. J Clin Oncol; 2007 Mar 10;25(8):971-7
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraoperative radiation therapy.
  • Intraoperative radiation therapy (IORT) is the delivery of irradiation at the time of an operation.
  • IORT is usually given in combination with external-beam radiation therapy with or without chemotherapy and surgical resection.
  • IORT excludes part or all dose-limiting sensitive structures, thereby increasing the effective dose to the tumor bed (and therefore local control) without significantly increasing normal tissue morbidity.
  • Despite best contemporary therapy, high rates of local failure occur in patients with locally advanced or recurrent rectal cancer, retroperitoneal sarcoma, select gynecologic cancers, and other malignancies.
  • The addition of IORT to conventional treatment methods has improved local control as well as survival in many disease sites in both the primary and locally recurrent disease settings.
  • Given newer and lower cost treatment devices, the use of IORT in clinical practice will likely grow, with increasing integration into the treatment of nonconventional malignancies.
  • [MeSH-major] Brachytherapy / methods. Electrons / therapeutic use. Neoplasms / radiotherapy
  • [MeSH-minor] Breast Neoplasms / radiotherapy. Humans. Radiotherapy Dosage. Radiotherapy, Adjuvant. Rectal Neoplasms / radiotherapy

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17350946.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 35
  •  go-up   go-down


17. Berber E, Ari E, Herceg N, Siperstein A: Laparoscopic radiofrequency thermal ablation for unusual hepatic tumors: operative indications and outcomes. Surg Endosc; 2005 Dec;19(12):1613-7
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: There is increasing experience with laparoscopic radiofrequency ablation for the treatment of patients with hepatic metastasis from colorectal and neuroendocrine cancer and those with hepatocellular cancer.
  • Little is known about the outcomes for patients with other tumor types.
  • Among these, 53 patients (10%) had cancers other than the colorectal, neuroendocrine, or hepatocellular types including sarcoma (n = 18), breast cancer (n = 10), esophagus cancer (n = 4), melanoma (n = 4), lung cancer (n = 3), ovarian cancer (n = 2), pancreas cancer (n = 2), unknown primary cancer (n = 2), cholangiocarcinoma (n = 2), rectal squamous cancer (n = 2), renal cancer (n = 2), papillary thyroid cancer (n = 1), and hemangioendothelioma (n = 1).
  • Unlike the criteria for treatment of the more usual tumor types, these patients had a diagnosis of liver-exclusive disease, as diagnosed by preoperative imaging.
  • They also had failed chemotherapy.
  • RESULTS: The 53 patients underwent ablation of 192 lesions, with 8 patients undergoing repeat treatment.
  • The overall median survival was 33 months for the whole series, more than 51 months for breast cancer, and 25 months for sarcoma.
  • CONCLUSION: Laparoscopic radiofrequency ablation can safely and effectively treat hepatic metastasis of these unusual tumor types.
  • The authors believe that this heterogeneous group of patients, selected for their unusual presentation of liver-exclusive disease, may benefit from cytoreduction of their tumor by laparoscopic radiofrequency ablation when other treatment methods have failed.
  • [MeSH-minor] Female. Humans. Male. Middle Aged. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Endosc. 2000 Apr;14(4):400-5 [10790563.001]
  • [Cites] World J Surg. 2002 Aug;26(8):985-90 [12016479.001]
  • [Cites] Surg Endosc. 2005 May;19(5):710-4 [15759186.001]
  • [Cites] Am J Surg. 2003 Feb;185(2):158-64 [12559448.001]
  • [Cites] Hepatogastroenterology. 1998 Jan-Feb;45(19):201-5 [9496513.001]
  • [Cites] Am Surg. 1999 Nov;65(11):1009-14 [10551746.001]
  • [Cites] World J Surg. 1995 Jan-Feb;19(1):72-5 [7740813.001]
  • [Cites] J Gastrointest Surg. 1998 Mar-Apr;2(2):151-5 [9834411.001]
  • [Cites] Surgery. 1997 Jun;121(6):625-32 [9186462.001]
  • [Cites] Arch Surg. 2001 Aug;136(8):950-5 [11485537.001]
  • [Cites] Ann Surg Oncol. 2001 May;8(4):379-80 [11352313.001]
  • [Cites] Cancer. 1995 Oct 1;76(7):1120-5 [8630886.001]
  • [Cites] Ann Surg Oncol. 2000 Mar;7(2):106-13 [10761788.001]
  • [Cites] Ann Surg. 1999 Jul;230(1):1-8 [10400029.001]
  • [Cites] Oncologist. 2003;8(3):241-51 [12773746.001]
  • [Cites] Surgery. 1997 Dec;122(6):1147-54; discussion 1154-5 [9426432.001]
  • [Cites] Ann Surg. 1995 Apr;221(4):392-7 [7726675.001]
  • [Cites] Ann Surg. 2001 Oct;234(4):540-7; discussion 547-8 [11573047.001]
  • [Cites] Arch Surg. 2001 Aug;136(8):864-9 [11485520.001]
  • [Cites] J Vasc Interv Radiol. 1999 Jul-Aug;10(7):907-16 [10435709.001]
  • [Cites] J Surg Res. 1999 Nov;87(1):114-21 [10527712.001]
  • [Cites] J Clin Oncol. 2005 Mar 1;23(7):1358-64 [15684312.001]
  • [Cites] Ann Thorac Surg. 2003 Jul;76(1):291-3 [12842567.001]
  • (PMID = 16247574.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


18. Ryan P, Nguyen VH, Gholoum S, Carpineta L, Abish S, Ahmed NN, Laberge JM, Riddell RH: Polypoid PEComa in the rectum of a 15-year-old girl: case report and review of PEComa in the gastrointestinal tract. Am J Surg Pathol; 2009 Mar;33(3):475-82

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polypoid PEComa in the rectum of a 15-year-old girl: case report and review of PEComa in the gastrointestinal tract.
  • We report PEComa with lymph node involvement occurring in the rectum of a 15-year-old girl, treated by surgical resection and adjuvant chemotherapy.
  • We review the differential diagnosis of intestinal PEComa, which includes malignant melanoma, epithelioid gastrointestinal stromal tumors, clear cell sarcoma of soft parts, alveolar soft part sarcoma, leiomyosarcoma with HMB45 expression, and paraganglioma.
  • Immunohistochemistry can rule out many of these morphologically similar tumors but differentiation from clear cell sarcoma may require reverse transcription-polymerase chain reaction.
  • [MeSH-major] Perivascular Epithelioid Cell Neoplasms / pathology. Rectal Neoplasms / pathology
  • [MeSH-minor] Adolescent. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Diagnosis, Differential. Digestive System Surgical Procedures. Female. Humans. Immunohistochemistry. Microscopy, Electron, Transmission. Reverse Transcriptase Polymerase Chain Reaction. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19092636.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


19. Tanigawa M, Kimura M, Ichioka M, Saito K, Kimura M: [A case of true pulmonary carcinosarcoma]. Nihon Kokyuki Gakkai Zasshi; 2003 Jul;41(7):496-501
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The diagnosis was therefore true pulmonary carcinosarcoma.
  • The sarcoma component recurred in the remaining part of the left lung.
  • Nevertheless, chemotherapy, linac radiosurgery, percutaneous radiofrequency ablation, and partial small intestinal resection combined with rectal resection were performed.
  • Liver metastatic lesions were determined to be the adenocarcinomatous component, and the other recurrent or metastatic lesions, except for those in the brain, were all composed of poorly-differentiated sarcomatous tissue.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12931680.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


20. Hegewisch-Becker S, Hossfeld DK: [Addition of hyperthermia. Heat potentiates cancer therapy]. MMW Fortschr Med; 2001 Jun 21;143(25):28-32

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Addition of hyperthermia. Heat potentiates cancer therapy].
  • It has been unequivocally demonstrated that hyperthermia (40-44 degrees C) has an potentiating effect on radiotherapy and chemotherapy.
  • Technical improvements have facilitated the application of both local and whole-body hyperthermia, and have thus made this form of treatment available to large numbers of patients.
  • The effectiveness of other procedures such as the combination of radio- and chemotherapy with regional hyperthermia, regional thermochemotherapy and whole-body hyperthermia has so far been investigated mainly in phase II studies focusing on head and neck cancer, cervical and ovarian cancer, sarcoma, malignant germ cell tumors, and rectal carcinoma.
  • However, the actual place of hyperthermia as a permanent element in a multimodal therapeutic concept has yet to be shown in prospective phase III studies.
  • [MeSH-major] Hyperthermia, Induced / instrumentation. Neoplasms / therapy
  • [MeSH-minor] Combined Modality Therapy. Equipment Design. Humans. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11468993.001).
  • [ISSN] 1438-3276
  • [Journal-full-title] MMW Fortschritte der Medizin
  • [ISO-abbreviation] MMW Fortschr Med
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


21. Ueda T, Emoto M, Fukuoka M, Miyahara D, Horiuchi S, Tsujioka H, Kawarabayashi T: Primary leiomyosarcoma of the fallopian tube. Int J Clin Oncol; 2010 Apr;15(2):206-9
Genetic Alliance. consumer health - Leiomyosarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary sarcoma of the fallopian tube is a very rare neoplasm.
  • The preoperative diagnosis was a left adnexal malignant tumor based on pelvic examination, abdominal computed tomography, and magnetic resonance imaging.
  • She was treated with total abdominal hysterectomy, bilateral salpingo-oophorectomy, pelvic lymph node dissection, partial omentectomy, and low anterior resection for rectal invasion.
  • The patient subsequently received adjuvant chemotherapy with pirarubicin and ifosfamide.
  • Thirty months after the first therapy, a computed tomography scan revealed metastasis of the liver, lung, and supraclavicular lymph node.
  • The patient died of the disease 39 months after the initial treatment.
  • [MeSH-major] Fallopian Tube Neoplasms / diagnosis. Leiomyosarcoma / diagnosis
  • [MeSH-minor] Aged. Biopsy. Chemotherapy, Adjuvant. Fatal Outcome. Female. Humans. Hysterectomy. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Lymph Node Excision. Lymphatic Metastasis. Magnetic Resonance Imaging. Omentum / surgery. Ovariectomy. Rectum / pathology. Rectum / surgery. Time Factors. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 1996 Apr;61(1):27-30 [8626112.001]
  • [Cites] Gynecol Oncol. 2003 Jun;89(3):460-9 [12798712.001]
  • [Cites] J Obstet Gynaecol Br Commonw. 1973 Aug;80(8):759-60 [4725957.001]
  • [Cites] Acta Obstet Gynecol Scand. 1992 Apr;71(3):224-5 [1317647.001]
  • [Cites] Cancer. 1983 Aug 15;52(4):626-32 [6344983.001]
  • [Cites] Br J Radiol. 2008 Jan;81(961):73-81 [17681989.001]
  • [Cites] Gynecol Oncol. 2008 Jun;109(3):329-34 [18534250.001]
  • [Cites] Gynecol Oncol. 2006 May;101(2):363-6 [16439005.001]
  • [Cites] Eur J Gynaecol Oncol. 2005;26(3):333-5 [15991540.001]
  • [Cites] Gynecol Oncol. 1993 Dec;51(3):404-7 [8112653.001]
  • [Cites] Am J Obstet Gynecol. 1958 Jan;75(1):180-2 [13487699.001]
  • [Cites] Cancer. 2004 Apr 1;100(7):1498-506 [15042685.001]
  • [Cites] Zentralbl Gynakol. 1997;119(5):237-40 [9281259.001]
  • (PMID = 20191300.001).
  • [ISSN] 1437-7772
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


22. O'Connell JB, Maggard MA, Ko CY: Cancer-directed surgery for localized disease: decreased use in the elderly. Ann Surg Oncol; 2004 Nov;11(11):962-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Previous studies report underuse of radiation and chemotherapy in the elderly, yet few have examined the rates of use (or underuse) of surgery.
  • METHODS: By using the Surveillance, Epidemiology, and End RESULTS database (1988-1997), patients (> or =40 years) were identified with localized adenocarcinoma of the breast, esophagus, stomach, pancreas, colon, or rectum; non-small-cell lung carcinoma; and sarcoma (n = 200,360).
  • However, CDS rates were >90% for breast and colon and >84% for rectal cancer in all age groups.
  • CONCLUSIONS: Although CDS for localized disease is being performed regularly in the elderly for some cancers (e.g. breast, colon, and rectum), this analysis shows that elderly patients are not receiving surgery for many potentially curable cancers.

  • MedlinePlus Health Information. consumer health - Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg Oncol. 2004 Nov;11(11):951-2 [15525821.001]
  • (PMID = 15525824.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Van der Aa F, Sciot R, Blyweert W, Ost D, Van Poppel H, Van Oosterom A, Debiec-Rychter M, De Ridder D: Gastrointestinal stromal tumor of the prostate. Urology; 2005 Feb;65(2):388
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Digital rectal examination revealed a large prostate with a parenchymal mass on the left side.
  • A pathologic diagnosis of a prostatic gastrointestinal stromal tumor was made and was confirmed by molecular analysis.
  • Therapy consisted of a tyrosine kinase inhibitor, resulting in prostate mass reduction.
  • [MeSH-major] Prostatic Neoplasms / radiography. Sarcoma / radiography
  • [MeSH-minor] Acute Disease. Amino Acid Substitution. Antineoplastic Agents / therapeutic use. Benzamides. Humans. Imatinib Mesylate. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Male. Middle Aged. Mutation, Missense. Neoplasm Proteins / genetics. Piperazines / therapeutic use. Protein Kinase Inhibitors / therapeutic use. Proto-Oncogene Proteins c-kit / genetics. Pyrimidines / therapeutic use. Urinary Retention / etiology. Weight Loss

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15708062.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Neoplasm Proteins; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


24. Camacho LH, Olson J, Tong WP, Young CW, Spriggs DR, Malkin MG: Phase I dose escalation clinical trial of phenylbutyrate sodium administered twice daily to patients with advanced solid tumors. Invest New Drugs; 2007 Apr;25(2):131-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Twenty-one patients with the following malignancies were treated: colon carcinoma 4, non-small cell lung carcinoma 4; anaplastic astrocytoma 3, glioblastoma multiforme 3, bladder carcinoma 2, sarcoma 2, and ovarian carcinoma, rectal hemangiopericytoma, and pancreatic carcinoma 1 each.
  • The therapy was well tolerated overall.
  • Study designs with more convenient treatment schedules and specific molecular correlates may help to further delineate the mechanism of action of this compound.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Neoplasms / drug therapy. Phenylbutyrates / therapeutic use
  • [MeSH-minor] Adult. Aged. Biotransformation. Disease Progression. Dose-Response Relationship, Drug. Female. Humans. Infusions, Intravenous. Male. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1992 Nov 15;80(10):2604-9 [1421378.001]
  • [Cites] Clin Cancer Res. 1996 Feb;2(2):379-87 [9816181.001]
  • [Cites] J Neurosurg. 1995 Oct;83(4):672-81 [7674018.001]
  • [Cites] Angiology. 1956 Apr;7(2):156-8 [13314153.001]
  • [Cites] Blood. 1993 Oct 1;82(7):2203-9 [7691251.001]
  • [Cites] Adv Exp Med Biol. 1997;400A:501-5 [9547596.001]
  • [Cites] Clin Cancer Res. 2001 Oct;7(10):3047-55 [11595694.001]
  • [Cites] Anticancer Res. 1998 Mar-Apr;18(2A):1099-103 [9615772.001]
  • [Cites] Cancer Res. 1988 Dec 15;48(24 Pt 1):7304-9 [3191501.001]
  • [Cites] J Clin Pharmacol. 1995 Apr;35(4):368-73 [7650225.001]
  • [Cites] Neuro Oncol. 2005 Apr;7(2):177-82 [15831235.001]
  • [Cites] Med Pediatr Oncol. 2000 Dec;35(6):577-81 [11107121.001]
  • [Cites] Int J Oncol. 1998 Apr;12(4):889-93 [9499451.001]
  • [Cites] Br J Haematol. 1991 Oct;79 Suppl 1:81-3 [1931716.001]
  • [Cites] Ther Drug Monit. 1996 Dec;18(6):714-20 [8946671.001]
  • [Cites] Cancer Res. 1994 Apr 1;54(7):1690-4 [8137283.001]
  • [Cites] Cancer Chemother Pharmacol. 2001 May;47(5):385-90 [11391852.001]
  • [Cites] Leukemia. 2006 Feb;20(2):212-7 [16357841.001]
  • [Cites] J Clin Oncol. 2005 Jun 10;23(17):3906-11 [15851763.001]
  • [Cites] Stat Med. 1991 Nov;10(11):1647-64 [1792460.001]
  • [Cites] Cancer Res. 1992 Apr 1;52(7):1988-92 [1372534.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):963-70 [11948101.001]
  • [Cites] N Engl J Med. 1984 Jun 21;310(25):1630-4 [6427608.001]
  • [Cites] Clin Cancer Res. 1996 May;2(5):865-72 [9816242.001]
  • [Cites] Blood. 1989 Apr;73(5):1298-306 [2467706.001]
  • [Cites] Cancer Res. 2001 May 15;61(10):3998-4002 [11358817.001]
  • [Cites] Pediatr Res. 1991 Feb;29(2):147-50 [2014149.001]
  • [Cites] Int J Cancer. 1995 Feb 8;60(4):507-14 [7829265.001]
  • [Cites] Clin Cancer Res. 1999 Jun;5(6):1509-16 [10389940.001]
  • [Cites] Jpn J Ophthalmol. 2000 Nov-Dec;44(6):601-9 [11094173.001]
  • [Cites] J Cell Biochem. 2004 Nov 1;93(4):819-29 [15389886.001]
  • [Cites] Am J Physiol. 1998 May;274(5 Pt 1):E801-7 [9612237.001]
  • [Cites] Blood. 1992 Sep 15;80(6):1576-81 [1381630.001]
  • [Cites] Cell Growth Differ. 1996 Dec;7(12):1609-15 [8959328.001]
  • [Cites] Clin Cancer Res. 2001 Aug;7(8):2292-300 [11489804.001]
  • [Cites] Cancer. 1995 Jun 15;75(12):2932-8 [7773944.001]
  • [Cites] Cancer Res. 1994 Jun 1;54(11):2923-7 [8187079.001]
  • [Cites] Anticancer Res. 2004 Sep-Oct;24(5A):2765-71 [15517883.001]
  • [Cites] Leukemia. 1999 Aug;13(8):1243-53 [10450753.001]
  • [Cites] J Natl Cancer Inst. 1998 Nov 4;90(21):1621-5 [9811311.001]
  • (PMID = 17053987.001).
  • [ISSN] 0167-6997
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U01: CA69856
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Phenylbutyrates
  •  go-up   go-down


25. Sakar B, Basaran G, Basaran M: Ewing's sarcoma of the rectum: are four cycles of chemotherapy enough? J Clin Oncol; 2005 Aug 20;23(24):5849-50; author reply 5850
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ewing's sarcoma of the rectum: are four cycles of chemotherapy enough?
  • [MeSH-major] Rectal Neoplasms / pathology. Rectal Neoplasms / therapy. Sarcoma, Ewing / pathology. Sarcoma, Ewing / therapy
  • [MeSH-minor] Combined Modality Therapy. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] J Clin Oncol. 2005 Feb 1;23(4):910-2 [15681537.001]
  • [ErratumIn] J Clin Oncol. 2005 Oct 1;23(28):7251
  • (PMID = 16110043.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  •  go-up   go-down






Advertisement